Hansoh Pharmaceutical Group Co Ltd is a pharmaceutical company integrating research and development, manufacturing, and sales. The company focuses on therapeutic areas including oncology, metabolism, immunology, central nervous system disorders, and anti-infectives. Its product portfolio includes Ameile (aumolertinib), Hansoh Xinfu (flumatinib), Fulaimei (PEG-loxenatide), Xinyue (inebilizumab), Hengmu (tenofovir amibufenamide), and Mailingda (morinidazole), alongside products such as Pulaile, Xintai, Xinwei, and Tanneng. The company maintains R&D centers in Shanghai, Lianyungang, Changzhou, and Maryland, USA, and has established out-licensing partnerships with GSK, MSD, Regeneron, and Roche. Founded in 1995, the company serves markets in China and internationally, with products approved in Europe, the United States, and Japan.

Summarised from the company's own disclosures, fiscal year ended Apr 2025

Industry Drug Manufacturers - General Homepage hspharm.com
Sector Healthcare IR page hspharm.com/investment
Tags
oncology, metabolism, immunology, central nervous system, anti-infectives, antibody-drug conjugates, sirna, bispecific antibodies, small molecules, innovative drugs, Ameile, Hansoh Xinfu, Fulaimei, Xinyue, Hengmu, Mailingda, Pulaile, Xintai, Xinwei, Tanneng, Fulaidi, Fulairui, Oulanning, Ailanning, Ameining, Zetan, Hengsen, HS-20118, HS-20110, HS-20094, HS-10535, LP-168, QX004N, HS-20117, HS-20089, HS-20093, Aumseqa
Press page hspharm.com/news

Metrics

Valuation  
Market cap HK$ 196.59B
Market cap (USD) $ 25.054B
P/E 31.04
PEG 1.07
P/BV 4.42
P/S 10.51
P/OCF 30.54
P/FCF —
Dividend yield 1.5%
Turnover / mcap 0.12%
Returns  
ROE 17.3%
ROI 15.7%
ROIC 15.7%
Profit margin 37.0%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y No
Earnings growth 3y (net profit CAGR) 29.1%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 10.8%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score 23.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Revenue 15.028B 12.261B 10.104B 9.382B 9.935B 8.69B 8.683B 7.722B
Net profit 5.555B 4.372B 3.278B 2.584B 2.713B 2.569B 2.557B 1.903B

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Share price — 18.38 — — — — — —
P/OCF — 28.29 — — — — — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Release Date:2026/10/28

Font Size

- HS-20108 has demonstrated a manageable safety profile and encouraging anti-tumor activity in patients with advanced solid tumors (2.0-6.0 mg/kg, administered intravenously once every 3 weeks), with particularly pronounced activity in small cell lung cancer (SCLC) patients who have received prior platinum-based chemotherapy.

SHANGHAI, October 28, 2026 — Hansoh Pharmaceutical Group Co., Ltd. ("Hansoh Pharma," 03692.HK) today announced that preliminary results from the Phase 1 clinical study of HS-20108 were presented in a poster session at the 2026 Annual Meeting of the European Society for Medical Oncology (ESMO). HS-20108 demonstrated a manageable safety profile and preliminary efficacy in the advanced solid tumor population, with particularly pronounced anti-tumor activity in small cell lung cancer (SCLC) patients who have received prior platinum-based chemotherapy.

HS-20108 is a proprietary antibody-drug conjugate (ADC) targeting SEZ6, developed by Hansoh Pharma, comprising a fully human anti-SEZ6 monoclonal antibody conjugated to a topoisomerase I inhibitor (TOP1i) payload via a linker. It is currently under clinical development for indications including small cell lung cancer (SCLC) and neuroendocrine tumors (NEN). The current ESMO 2026 data disclose the preliminary monotherapy results of this drug in patients with advanced solid tumors.

Details of the Poster Presentation

• Poster Title: Phase 1 Study of HS-20108, a SEZ6-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors

• Presentation Format: Poster

• FPN: 3814P

• Date/Time: Mon. 26.10.2026 (12:00-12:45) CET

• Presenter: Prof. Shengxiang Ren, Shanghai Pulmonary Hospital

About the HS-20108-101 Study

HS-20108-101 (NCT06936735) is a first-in-human, multicenter, open-label Phase 1 trial conducted in China evaluating the safety, tolerability, pharmacokinetic (PK) profile, and preliminary anti-tumor activity of HS-20108 in patients with advanced solid tumors. The study comprises a Phase 1a dose-escalation phase (2.0-6.0 mg/kg, administered intravenously once every 3 weeks) and a Phase 1b dose-expansion phase. The primary endpoints are the maximum tolerated dose (MTD)/maximum administered dose (MAD) and the objective response rate (ORR) assessed by investigators per RECIST v1.1.

As of the data cutoff (12 August 2026), a total of 96 patients with advanced solid tumors were enrolled, with a median follow-up time of 4.53 months (range: 0.1-14.5 months). The data in the advanced solid tumor population are as follows:

Encouraging anti-tumor activity:

• Tumor responses were observed across all dose groups (2.0-6.0 mg/kg, N=90): the unconfirmed ORR (uORR) was 51.1%, the confirmed ORR (cORR) was 41.1%, and the disease control rate (DCR) was 95.6%;

• Efficacy was particularly pronounced in SCLC patients (4.0/5.0 mg/kg cohorts, N=55): uORR was 65.4%/58.6%, cORR was 57.7%/44.8%, and DCR was 100.0%/96.6%, respectively.

• In SCLC patients who had received prior first-line therapy (i.e., second-line therapy) (4.0/5.0 mg/kg cohorts, N=33): uORR reached 75.0%/64.7%, cORR was 68.8%/52.9%, and the DCR in both dose cohorts was 100.0%, further supporting the treatment potential of HS-20108 in second-line SCLC.

Manageable safety:

• Only one dose-limiting toxicity (DLT) was reported (in the 6.0 mg/kg cohort, grade 4 thrombocytopenia); no infusion-related reactions were reported;

• Grade ≥3 treatment-related adverse events (TRAEs) were mainly hematologic and gastrointestinal events, all of which were manageable and resolved rapidly following treatment;

• One SCLC patient reported grade 3 treatment-related interstitial lung disease (ILD; this event was also considered possibly related to prior immuno-oncology therapy). One grade 5 adverse event was reported (preferred term: disease progression);

• Overall, HS-20108 demonstrated a manageable safety profile in patients with advanced solid tumors, and the safety profile in SCLC patients was generally consistent with that of the overall population.

Hansoh Pharma will continue to be driven by patient needs, deepening the clinical layout of HS-20108 across multiple tumor types, multiple lines of therapy, and various combination regimens, fully exploiting the therapeutic potential of the SEZ6-targeting ADC, advancing Chinese innovation to the world, and providing more effective and accessible disease solutions for patients globally.

About Small Cell Lung Cancer

In 2022, an estimated 1.06 million new cases of lung cancer and 733,300 lung cancer-related deaths were reported in China, making lung cancer the most common cancer and the leading cause of cancer-related mortality in the country [1]. Small cell lung cancer (SCLC) accounts for approximately 10%–5% of all lung cancer cases [2] and is characterized by its highly aggressive nature, early development of widespread metastases, high risk of recurrence, and poor prognosis [3].

SCLC is broadly classified into limited-stage disease (LS-SCLC) and extensive-stage disease (ES-SCLC). Treatment for LS-SCLC may include surgery and concurrent chemoradiotherapy; however, the 5-year survival rate remains only approximately 30%–35% [4]. Approximately 60%–70% of patients with SCLC are diagnosed with extensive-stage disease, for which palliative systemic therapy, primarily chemotherapy, is the mainstay of treatment. Patients with ES-SCLC have a particularly poor prognosis, with a median overall survival of only 7–12 months [5] and a 2-year survival rate of approximately 22% [6], underscoring the high unmet medical need and the urgency of developing innovative therapies.

References

[1] Zheng RS, Chen R, Han BF, et al. Cancer incidence and mortality in China, 2022. Chinese Journal of Oncology. 2024;46(3):221-231.

[2] Kim SY, Park HS, Chiang AC. Small Cell Lung Cancer: A Review. JAMA. 2025 Jun 3;333(21):1906-1917.

[3] Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer. Nat Rev Dis Primers. 2021;7(1):3.

[4] Higgins KA, Gorgens S, Sudmeier LJ, Faivre-Finn C. Recent developments in limited stage small cell lung cancer. Transl Lung Cancer Res. 2019;8(Suppl 2): S147-S152.

[5] Wang S, Zimmermann S, Parikh K, Mansfield AS, Adjei AA. Current Diagnosis and Management of Small-Cell Lung Cancer. Mayo Clin Proc. 2019;94(8):1599-1622.

[6] Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer. Nat Rev Dis Primers. 2021;7(1):3.

About Hansoh Pharma

Hansoh Pharma is a leading innovation-driven pharmaceutical enterprise in China. With the mission of "continuous innovation for better life", the company focuses on major disease therapeutic areas such as oncology, metabolism, immunology, central nervous system (CNS) and anti-infectives. Hansoh Pharma has launched 7 innovative medicines that generate product sales in China, with the revenue from innovative medicines and collaborative products exceeding 80%, forming a rich product pipeline. The company has consistently ranked among the top 100 global pharmaceutical companies and is recognized as one of the top 3 pharmaceutical R&D enterprises in China, and is designated as a National Key High-Tech Enterprise and a National Technology Innovation Demonstration Enterprise. Hansoh Pharma was listed on the Hong Kong Stock Exchange in June 2019 (stock code: 03692.HK).

Statements

1. This announcement is intended for healthcare professionals only and not for advertising purposes.2. Hansoh Pharma does not recommend the use of any unapproved drugs or off-label indications, nor does it make recommendations regarding any drug or indication.3. The information provided in this announcement is for reference only; please follow the advice or guidance of a physician or other healthcare professional. Any treatment-related decisions made by healthcare professionals should be based on the specific circumstances of the patient and should be used in accordance with the instructions for the drug.4. For more detailed information about any company products, medical treatments, or diseases, please consult a healthcare professional.

Forward-Looking Statements

This press release is intended to provide information about Hansoh Pharmaceutical Group Co., Ltd. and its affiliates, including their subsidiaries (collectively referred to as "Hansoh Pharma"). It does not constitute a disclosure of information about Hansoh Pharma or any investment recommendations.The information contained in this release may include forward-looking statements related to Hansoh Pharma's business and product prospects, as well as its plans, beliefs, expectations, and strategies. These statements are predictions based on speculative assumptions and are not guarantees of future performance. They are subject to risks and uncertainties, such as scientific, commercial, political, economic, financial, legal factors as well as competitive environment and social conditions, many of which are beyond Hansoh Pharma's control and difficult to predict, thus actual results may differ significantly from what is stated here, and past securities price trends should not be used as a guide for future market conditions. As such, investors should exercise caution when using this information to make investment decisions. Phrases such as "commit," "expect," "believe," "predict," "anticipate," "forecast," "intent,"“project,” “may,” “will,” “should,” “plan,” “could,” “continue,” “target,” “contemplate,” “estimate,” “guidance,” “possible,” “potential,” “pursue,”“likely,”and words and terms of similar terms substance used in connection with any discussion of future plans, actions or events indicate forward-looking statements.Hansoh Pharma does not commit to or guarantee the accuracy, timeliness, or completeness of forward-looking information and assumes no obligation to update or revise these forward-looking statements. Neither Hansoh Pharma nor any of its directors, employees, or agents will be responsible for any forward-looking statements that prove to be inaccurate or unachievable and any losses or damages incurred by users due to reliance on the information provided herein, including but not limited to direct, incidental, indirect, or punitive damages.All information in this press release is current as of the date of release. Hansoh Pharma assumes no responsibility to update or revise this information in light of new developments, future events, or other circumstances, except as required by law. Additionally, Hansoh Pharma reserves the right to make changes, corrections, or discontinuations to all or part of the content of this press release at any time without notice. For information specifically related to the listed company, investors are encouraged to refer to the announcements and financial reports of Hansoh Pharma (03692.HK).

Previous

No Data!

Next

2026 ESMO | HANSOH PHARMA ANNOUNCES POSITIVE PRIMARY RESULTS FROM PHASE 3 ARTEMIS-011 STUDY OF RISVUTATUG REZETECAN (HS-20093) IN PATIENTS WITH RELAPSED OR REFRACTORY OSTEOSARCOMA

Back to list

News Recommendation

瀚森制药

Related Companies

About Us

Overview

History

Honor

Leadership

Contact Us

Innovation

Achievements

R&D Platforms

R&D Capability

Business Development

Manufacturing

Quality Management

Products

Our Products

Market Coverage

Investors

Company Information

Corporate Governance

Financial Information

Announcements and Circulars

Investor Contact

Sustainability

Compliance Management

ESG Governance

Practice and Honor

ESG Reports

Careers

Work with Us

Join Us

Follow Hansoh Pharma's WeChat Account

Follow Hansoh Pharma's WeChat Channel

Transfer to Pharmacovigilance

If you would like to report any adverse event involving Hansoh's products, please contact us by: Tel:+86-400-828-5227 or+86-518-83096666 E-mail:[email protected]

© 2026 Hansoh Pharmaceutical Group Company Limited. All rights reserved. Su ICP REF 12053606-4 (Su) - Non-Operational - 2020-0089 (Internet Drug Information Service)   Disclaimer

网站制作: Design by JEREI

Prompts

Hansoh Pharmaceutical Group Co Ltd (ticker 3692), listed in Hong Kong.

ETFs Holding Hansoh Pharmaceutical Group Co Ltd

ETF Weight in ETF Shares Market value As of
OZEM 3.77% 494,000 $ 2.104M Nov 17, 2026
PCCE 0.98% 4,000 $ 15.107K Jun 30, 2026
FFEM 0.84% 126,648 $ 519.679K Jul 31, 2026
FFGX 0.29% 37,909 $ 155.553K Jul 31, 2026
SEEM 0.26% 423,700 $ 1.6M Jun 30, 2026
REMG 0.08% 22,000 $ 83.087K Jun 30, 2026
DFSE 0.06% 74,000 $ 329.595K Nov 12, 2026
DFAE 0.04% 846,000 $ 3.768M Nov 12, 2026
AVEM 0.03% 1,734,000 $ 7.478M Nov 16, 2026
DFEM 0.03% 538,000 $ 2.396M Nov 12, 2026
NTSE 0.03% 4,000 $ 15.108K Jun 30, 2026
AVSE 0.02% 10,000 $ 43.124K Nov 16, 2026
DFAX 0.01% 182,000 $ 810.626K Nov 12, 2026